Wells Fargo Upgrades Cumberland Pharmaceuticals (CPIX) to Outperform; Reassessment Of Marketing Focus Could Drive Shares

Wells Fargo upgraded Cumberland Pharmaceuticals (NASDAQ: CPIX) from Market Perform to Outperform, price target range $9-$11.

Wells analyst says, "With IP position for Acetadote likely solidified for the foreseeable future (2025), we believe management is ready to reassess its marketing priorities and invest behind Acetadote, instead of continuing on the potentially futile path of driving Caldolor growth. Due largely to the failed Caldolor launch, CPIX shares are trading below their intrinsic value, as calculated by any typical valuation metric, in our view. Rearranging its marketing to make Acetadote the priority could drive meaningful share price appreciation."

For an analyst ratings summary and ratings history on Cumberland Pharmaceuticals click here. For more ratings news on Cumberland Pharmaceuticals click here.

Shares of Cumberland Pharmaceuticals closed at $7.59 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Aebi Schmidt Holding AG (AEBI) PT Raised to $17 at DA Davidson Following Q2 Results
• Semiconductor Manufacturing International Corp. (981:HK) (SMI) PT Raised to HK$153 at Goldman Sachs
• Terreno Realty Corp (TRNO) PT Raised to $77 at Cantor Fitzgerald on Leasing Optimism